Belgium issued a new law in November banning doctors from prescribing Ozempic and other GLP-1 drugs for weight loss unless a patients BMI is 35 or above and has one underlying health condition
Balancing cost-effectiveness with individual tolerance and side-effects ensures that treatment decisions reflect both clinical outcomes and quality-of-life considerations
PMC: Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss. New England Journal of Medicine: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. PMC: Who Wins the Battle Against Obesity
No two people have the exact same experience, but research helps show what weight loss often looks like on average
The Role of Pharmacy Guidance in Weight Loss Treatment Weight loss services that are operated by pharmacies offer a compromise between accessibility and clinical responsibility
Talenezhad N, Mohammadi M, Ramezani-Jolfaie N, Mozaffari-Khosravi H, Salehi-Abargouei A